|
Latest COMET data still give nod to carvedilol: unfair comparison with metoprolol? (Carvedilol or Metoprolol European Trial).(Cardiovascular Medicine)
Publication: Internal Medicine News Publication Date: 15-OCT-03 Author: Jancin, Bruce
|
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2003 International Medical News Group
VIENNA -- New data from the controversial Carvedilol or Metoprolol European Trial continue to demonstrate major, clinical advantages for carvedilol.
But COMET remains dogged by sharp criticism that dosage differences made for an unfair comparison in the trial, sponsored by Hoffmann La Roche and GlaxoSmith-Kline, developers of carvedilol.
COMET was a randomized, double-blind comparison of the effects of two different [beta]-blockers on outcomes in 3,028 patients with congestive heart failure (CHF). Both drugs had previously been shown to reduce mortality in landmark placebo-controlled trials; the question posed in COMET was whether the different pharmacologic profiles of the two drugs might...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from Internal Medicine News |
FDA approves new test for CHD biomarker: low LDL levels. (coronary hea...
October 15, 2003
|
Sizing up CHD risk factors. (coronary heart disease).(Clinical Capsule...
October 15, 2003
|
Conventional warfarin for VTE. (venous thromboembolism).(Clinical Caps...
October 15, 2003
|
Minor trauma, LAD dissection. (left anterior descending coronary arter...
October 15, 2003
|
Hearts of hemophilia carriers.(Clinical Capsules)(Brief Article)
October 15, 2003
|
|
| Find companies classified under Pharmaceutical preparations |
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
